What's Happening?
Ardena, a specialist in pharmaceutical contract development and manufacturing, has opened a new bioanalytical laboratory in Somerset, New Jersey. This facility, spanning over 2,500 square feet, enhances Ardena's scientific capabilities in North America,
providing biopharma companies with high-quality bioanalytical services. The laboratory is equipped with controlled sample storage, LC-MS/MS systems, and immunochemistry platforms, supporting both preclinical and clinical studies. This expansion allows Ardena to analyze a wide range of therapeutic modalities, including small and large molecules, and supports global clinical trials. The new laboratory complements Ardena's existing operations in Europe, enabling closer collaboration with clients during critical stages of drug development.
Why It's Important?
The establishment of this new laboratory is significant for the biopharmaceutical industry in the U.S., as it provides local access to advanced bioanalytical services. This development is likely to accelerate drug development processes by facilitating closer collaboration between Ardena and its clients. The expansion also strengthens Ardena's position in the global market, enhancing its ability to support complex therapeutic modalities and biomarker analysis. This move is expected to attract more biopharma companies to partner with Ardena, potentially leading to increased innovation and faster time-to-market for new therapies.
What's Next?
Ardena plans to further expand the Somerset site by adding more laboratory space and analytical platforms, including qPCR and flow cytometry. This expansion will be supported by a fully integrated electronic quality management system and laboratory information management system to ensure data integrity and efficient study execution. As demand for bioanalysis and biomarker services grows, Ardena is likely to continue investing in its capabilities to meet the needs of its clients.
